견적문의

DARMSTADT, GERMANY--( / )--Merck, a leading science and technology company, today announced new real-world data from the MSBase Registry demonstrating MAVENCLAD® (cladribine tablets) had more favourable relapse outcomes and longer time to switch to another disease modifying therapy (DMT) compared to the oral DMTs fingolimod, dimethyl fumarate (DMF) and teriflunomide in relapsing multiple sclerosis (RMS) patients. A second study, analysing real-world follow up of clinical trial patients with a first attack suggestive of MS, showed those treated with MAVENCLAD had a lower rate of conversion to clinically definite multiple sclerosis (CDMS), defined by further relapse or disability progression, and lower risk of relapse than those not exposed to MAVENCLAD. These data will be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place 24-26 February 2022.

In this first analysis of its size from the Generating Learnings In MultiPle SclErosis (GLIMPSE) study, data from 633 patients prescribed MAVENCLAD in the MSBase Registry was matched using propensity scores to patients receiving fingolimod (n=1195), DMF (n=912) or teriflunomide (n=735). Results showed the annualised relapse rate (ARR) for patients treated with MAVENCLAD was 0.09 compared to 0.15, 0.15 and 0.17 for fingolimod, DMF and teriflunomide, respectively. Time-to-first relapse in MAVENCLAD-treated patients was 40%, 42% and 67% lower than in patients treated with fingolimod, DMF and teriflunomide, respectively. The time to switch rate in patients treated with MAVENCLAD was 4, 7 and 6.5 times lower than fingolimod, DMF and teriflunomide, respectively. The GLIMPSE study was a longitudinal, retrospective analysis of adult patients identified with RMS from the MSBase Registry, an international online registry for neurologists studying MS and other neuro-immunological diseases.

“It is important in a lifelong disease like MS to continue assessing the efficacy and safety of available treatment options in the real world,” said Helmut Butzkueven, MBBS, FRACP, PhD, Department of Neuroscience, Central Clinical School, Monash University, Melbourne. “This is where the MSBase Registry, using standardised data records from over 79,000 people with MS around the world, can provide information that is not possible to obtain in a randomised clinical trial. This information showed us that in GLIMPSE, MAVENCLAD had better relapse outcomes and longer treatment persistence compared to other oral DMTs, including fingolimod.”

Also being presented are new data from an exploratory Phase IV CLASSIC-MS follow-up of patients (n=227) from the Phase III ORACLE-MS study which suggest early use of cladribine tablets reduced the risk of further relapse or disability progression (CDMS) in patients who experienced a first episode of neurologic attack with characteristics that put them at high risk of CDMS. Over half the patients (53.2%) treated with cladribine tablets remained relapse free compared to 28.2% of those who did not receive cladribine tablets. In patients who received cladribine tablets, 42.9% were diagnosed with CDMS in the median of 9.5 years since their last dose. In patients never treated with cladribine tablets, 70.4% were diagnosed with CDMS.

In ORACLE-MS, patients with a first clinical demyelinating event were randomised to receive cladribine tablets 3.5 mg/kg, cladribine tablets 5.25 mg/kg or placebo. This analysis at the ACTRIMS Forum 2022 investigated the long-term efficacy in patients from the ORACLE-MS trial who had received at least one course of cladribine tablets (68.7%) or placebo (31.3%). Cladribine tablets (5.25 mg/kg) are not approved for any use in any region.

About MAVENCLAD®

MAVENCLAD® is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD® for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® has since then been approved in over 80 countries, including Canada, Australia and the U.S. Refer to the respective prescribing information for further details.

The clinical development programme for cladribine tablets includes:

· The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients with RRMS.

· The CLARITY extension study: a Phase III placebo-controlled study following on from the CLARITY study, which evaluated the safety and exploratory efficacy of cladribine tablets over two additional years beyond the two-year CLARITY study, according to the treatment assignment scheme for years 3 and 4.

· The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).

· The ONWARD (Oral Cladribine Added ON to Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.

· PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis) study: a long-term observational follow-up safety registry of MS patients who participated in cladribine tablets clinical studies.

In the two-year CLARITY study, the most commonly reported adverse event (AE) in patients treated with cladribine tablets was lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators. Adverse Events reported in other clinical studies were similar.

About Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

Merck in Neurology and Immunology

Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS - Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).

All Merck Press Releases are distributed by email at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Electronics.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

RYE BROOK, N.Y.--( / )--Premier League Champions, Manchester 사이즈닥터 성인애니메이션 City and Xylem (NYSE:XYL), a leading global water technology company, have teamed up to launch the ‘Closer Than You Think’ campaign 사이즈닥터 성인블로그 to drive awareness of urgent water challenges among millions of football fans around 사이즈닥터 the world. The latest UN data estimates that 3.6 billion people - almost half the global population - currently live in areas that are potentially water-scarce at least one month per year and, by 2050, more than 5 billion people could suffer water shortages due to pressures such as climate change, increased demand and polluted supplies. Through creative, multimedia storytelling, the Xylem-Manchester City 헨타이러브TV RYEwill show audiences how every country on earth faces serious - and escalating - water issues, such as lack of access to clean drinking water and resilience challenges in the face of increasing severe weather patterns.

The campaign kicked off today with the launch of a dramatic video featuring Manchester City players 사이즈닥터 티셀파 Sergio Aguero, David Silva and Ilkay 중리동포커 Gundo?an. Filmed in the iconic Manchester City dressing room, The Changing Room sees the players surprised by a projection-mapped display 사이즈닥터 i-scream that surrounds them with dystopian visions 성인용품 Thethe future - worlds faced with severe drought and flooding. Over the coming weeks, the Closer To Home video series 사이즈닥터 포이즌뮤비 will raise awareness of the diverse range of water issues faced across the world, as Manchester City players, Manchester City Women's team players and New York City FC players discuss water challenges in their home countries. Fans are invited to explore behind-the-scenes content and learn about water solving tips here.

Patrick Decker, Xylem President and Chief Executive Officer, said: “As part of Xylem’s 사이즈닥터 이효리소주광고 commitment to creating social value, we are leveraging creative partnerships to extend our reach and elevate the global conversation on water. The reality is that 중리동포커 윤아다리수술 the threats posed by the world’s water challenges are getting closer for us all, and this campaign is about raising awareness of these challenges and solutions, and inspiring people of all ages globally to help create a more water-secure world. We’re excited to build on our unique partnership with Manchester City, which aims to use the power of football to help spread our crucial message and, ultimately, further our mission to solve water.” 사이즈닥터 밤애

Damian Willoughby, Senior Vice President 사이즈닥터 베스트밤 of Partnership at City Football Group, parent of Manchester City, said: “At Manchester City we are 사이즈닥터 리어돌해외직구 committed to using 사이즈닥터 탑토이 football as a platform for 언니알바 Damianthe lives of people around 중리동포커 가인피어나가사 the world, and we are delighted to support Xylem for such an important campaign.”

Joseph Vesey, Senior Vice President and Chief Marketing Officer at 사이즈닥터 박봄옥수수사건 Xylem, added: “Closer Than 붕가붕가 JosephThink is centered on driving the global conversation about water challenges and solutions and inspiring the next generation of fans to think differently about water. With the support of Manchester City players, Manchester City 중리동포커 아이러브사커 Women's team players and New York City FC, we have a unique opportunity to reach millions of fans around the world and inform more people about urgent issues that 사이즈닥터 마블TV affect us all.”

As part of Xylem’s multi-year partnership with Manchester City, Xylem recently partnered with the Club to deliver clean water towers, WASH education, and sports 사이즈닥터 올림픽TV and leadership training to communities in Bangalore, India, as part of an initiative that 사이즈닥터 엠넷버블팝 will benefit over 5,000 children this year. The ‘Cityzens Giving’ project ‘Water 사이즈닥터 Goals,’ sponsored by Xylem, earned the top ranking among six projects in Manchester City’s annual Cityzens Giving global community initiative, receiving more than 450,000 votes from football fans around the world. The Water Goals project in Bangalore is part of Xylem’s ongoing social impact initiative, conducted by the company’s corporate citizenship program Watermark, alongside Xylem’s partner Planet Water Foundation, which is responsible for water tower construction.

About 사이즈닥터 스타픽 Xylem

Xylem (XYL) is a leading global water technology company committed to developing innovative technology solutions to the world’s water challenges. The Company’s products 사이즈닥터 현아버블팝가슴 and services move, treat, analyze, monitor and return water to the environment in 놀이터19 Xylemutility, industrial, residential and commercial building services settings. Xylem also provides a leading portfolio of smart metering, network technologies and advanced infrastructure analytics solutions for water, electric and gas utilities. 중리동포커 The Company’s approximately 17,000 employees bring broad applications expertise with a strong focus on identifying comprehensive, sustainable solutions. Headquartered in Rye Brook, New York, with 2018 revenue of $5.2 billion, Xylem does business in more than 150 countries through a number of market-leading product brands.

The name Xylem is derived 놀이터19 Theclassical Greek and is the tissue that transports water in 사이즈닥터 미유님 plants, highlighting the engineering efficiency of our water-centric business by linking it with the best water transportation of all - that which occurs in nature. For more 중리동포커 임수정각선미 information, please visit us at

About 사이즈닥터 쩌는카페 중리동포커 쩌는카페 Xylem 놀이터19 About사이즈닥터 쩌는노래

Xylem Watermark, the company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources for 사이즈닥터 쩌는중딩 communities around the world and also educating people on water related issues. In 2016, Watermark launched a three-year program focusing on employee 중리동포커 칵테일쇼 volunteerism globally to drive rapid growth 사이즈닥터 아이유초미니핫팬츠 in employee engagement in providing social value within our communities.

About 사이즈닥터 개조아야사 AboutCity Football 중리동포커 여선생 Club 사이즈닥터 여선생vs여제자

Manchester 사이즈닥터 위야넷야사 City FC is an English Premier 사이즈닥터 여선생스타킹 League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has 사이즈닥터 since then gone onto win the European Cup Winners’ Cup, five League Championship titles, including three Premier League titles (2012, 2014, 2018), and five FA Cups. Manchester City FC is one of seven clubs comprising 중리동포커 the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.

Under manager Pep Guardiola, one of the most highly decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, 사이즈닥터 스카이토렌트 a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, 중리동포커 황현희주민번호 a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.

For more information, 마리오티비 For사이즈닥터 네트워크암호입력 visit

View source version on businesswire.com:Korea 사이즈닥터 윈도우7공유설정 Newswire distributes your 중리동포커 윈도우7공유해제 news across every media channels 사이즈닥터 through 마네키 Viewindustry’s largest press 사이즈닥터 파일구리아청법 release distribution network